Anticipating Financial Results from Ardelyx
WALTHAM, Mass. -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company dedicated to creating pioneering medications that address significant medical needs, is gearing up for an important event. The company will hold a conference call to discuss its financial results and a comprehensive business update for the full year and fourth quarter of 2024.
Details of the Conference Call
Scheduled for February, the call will take place at 8:00 a.m. Eastern Time. Participants can join by calling either (877) 346-6112 for domestic listeners or (848) 280-6350 for those calling internationally. This session provides an invaluable opportunity for investors and analysts to hear directly from Ardelyx about the company's financial performance and strategic direction.
How to Access the Live Webcast
The conference call will also be available via a live webcast. Individuals interested in accessing the webcast can find it under the Investors section of the Ardelyx website. Furthermore, a recording of the event will be archived and accessible for replay for up to 30 days, ensuring that all interested parties have the chance to catch up on the discussion.
An Overview of Ardelyx
Ardelyx was established with the vision of developing and commercializing innovative, first-in-class medicines. The company is focused on creating treatments that significantly impact patients with unmet medical requirements. Currently, Ardelyx’s commercial offerings include two notable products that have received approval in the United States: IBSRELA (tenapanor) and XPHOZAH (tenapanor).
Global Collaboration for Expansion
Ardelyx is expanding its reach by collaborating with international partners. For example, Kyowa Kirin is commercializing PHOZEVEL (tenapanor) for treating hyperphosphatemia in Japan. Additionally, a New Drug Application for tenapanor addressing hyperphosphatemia has been filed in China through a partnership with Fosun Pharma. In Canada, Knight Therapeutics is responsible for the commercialization of IBSRELA. These collaborations demonstrate the company’s commitment to broadening access to its innovative therapies.
Focus on Long-term Growth
Looking ahead, Ardelyx remains dedicated to its mission and is actively working on advancing its portfolio. The upcoming financial results will shed light on the company’s achievements over the past year, including any updates regarding ongoing research and developments in their product pipeline. It will be interesting to see how Ardelyx continues to navigate the complexities of the biopharmaceutical landscape.
Investor Relations Contact
Caitlin Lowie is the primary contact for investors and media inquiries. She is available at the company’s official email to provide further information and insights.
Frequently Asked Questions
What is Ardelyx's main focus?
Ardelyx focuses on developing innovative, first-in-class medicines for significant unmet medical needs.
When will Ardelyx report its financial results?
Ardelyx is scheduled to report its financial results on February 20, 2025.
How can I participate in the conference call?
Participants can join the call by dialing (877) 346-6112 for domestic calls or (848) 280-6350 for international calls.
Where can I access the webcast of the conference call?
The live audio of the conference call will be available on the Ardelyx website under the Investors section.
What products does Ardelyx have approved in the US?
Ardelyx has two products approved in the US: IBSRELA and XPHOZAH, both formulations of tenapanor.
